Abemaciclib and PI3K Inhibitor Combination for Mantle Cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma with limited treatment options and poor prognosis, often associated with significant adverse side effects from current therapies.
Innovation Solution
The combination of abemaciclib, a CDK inhibitor, with a PI3K and/or mTOR inhibitor, such as copanlisib, offers a new treatment approach for MCL, potentially providing enhanced therapeutic effects and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy regimens are used to treat mantle cell lymphoma, then tumor control may be achieved, but significant adverse side effects occur including neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhoea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia
Solution Approach 1:
The patent changes the therapeutic parameters by switching from conventional chemotherapy agents to a combination of abemaciclib (a CDK4/6 inhibitor) and a PI3K and/or mTOR inhibitor. This parameter change targets specific molecular pathways (cell cycle regulation and phosphoinositide signaling) rather than non-specific cytotoxic effects, thereby maintaining tumor control while reducing adverse side effects associated with traditional chemotherapy
Solution Approach 2:
The patent replaces the mechanical/cytotoxic mechanism of conventional chemotherapy with a molecularly targeted mechanism. Instead of using drugs that physically damage dividing cells, the invention uses inhibitors that specifically block molecular pathways (CDK4/6 and PI3K/mTOR) critical for tumor cell survival and proliferation, thereby achieving therapeutic effects with reduced toxicity
2Productivity
If targeted agents such as ibrutinib, lenalidomide, bortezomib, or venetoclax are used as monotherapies for MCL, then initial treatment response may be achieved, but resistance develops and treatment ultimately becomes unsuccessful
Solution Approach 1:
The patent merges two different molecularly targeted agents (abemaciclib targeting CDK4/6 and a PI3K/mTOR inhibitor targeting the phosphoinositide pathway) into a combination therapy. This combination approach addresses multiple critical pathways simultaneously, preventing the development of resistance that occurs with monotherapy and thereby improving long-term treatment success while maintaining initial response rates
3Reliability
If intensive chemotherapy with autologous stem cell transplant is administered to transplant-eligible patients, then initial disease control is achieved, but patients eventually relapse with progressive clinical course
Solution Approach 1:
The patent changes the therapeutic parameter from intensive chemotherapy with stem cell transplant to molecularly targeted inhibition of specific pathways (CDK4/6 and PI3K/mTOR). This approach provides sustained disease control by continuously blocking the molecular drivers of lymphoma progression, potentially extending disease-free survival beyond what is achieved with conventional intensive therapy
Data Source
AI summary
Provided herein is a combination therapy for use in a method of treating mantle cell lymphoma in a patient in need thereof.